Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

postmenopausal osteoporosis

Investing in the future of R&D

Roch Doliveux on UCB’s research plans and paying for innovation

- PMLiVE

Amgen files breakthrough leukaemia antibody in US

Already received top status from the FDA for the treatment of ALL

- PMLiVE

Amgen submits melanoma and cholesterol drugs to EMA

Regulator will assess talimogene laherparepvec and evolocumab

- PMLiVE

UCB wins new epilepsy indication for Vimpat in the US

FDA approves drug as monotherapy in patients with partial-onset seizures

- PMLiVE

Amgen claims first-to-file spot in PCSK9 inhibitor race

Evolocumab is part of new class of treatment to tackle high cholesterol

- PMLiVE

Amgen gets priority review for chronic heart failure hope

Raises expectations for early entry onto US market for ivabradine

Elliott Levy joins Amgen from BMS

He is appointed senior VP, global development

- PMLiVE

Amgen hit as Kyprolis fails myeloma study

Inability to improve overall survival could dent expanded use prospects

- PMLiVE

UCB joins clinical trial data sharing portal

Follows GSK, Lilly, Roche and others in committing to transparency website

- PMLiVE

Amgen closes on second-line use for Kyprolis

Multiple myeloma therapy posts positive interim phase III results

- PMLiVE

Amgen cuts workforce and facilities despite profit leap

US biopharma plans 12-15 per cent workforce reduction

- PMLiVE

Amgen launches bowel cancer web portal in Spain

Aims to help healthcare professionals understand about personalised medicine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links